Press Releases GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:16 2024-11-29 am EST			5-day change	1st Jan Change
1,335.00 ^GBX	-0.41%		-0.52%	-7.94%

Nov. 29	Wall Street hit by turkey coma
Nov. 29	Intron Health Downgrades GSK to Sell, Cuts PT	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GSK : fully liquid Menveo meningococcal vaccine approved by European Commission Form 6 K	Nov. 27	PU
GSK's fully liquid Menveo meningococcal vaccine approved by European Commission	Nov. 27	AQ
GSK : fully liquid Menveo meningococcal vaccine approved by European Commission	Nov. 27	PU
GSK : Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma Form 6 K	Nov. 25	PU
Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma \| GSK	Nov. 25	AQ
Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan \| GSK	Nov. 22	AQ
GSK : Arexvy approval expanded to adults aged 50 59 at increased risk of severe RSV disease in Japan Form 6 K	Nov. 22	PU
GSK : Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan	Nov. 22	PU
GSK plc - Linerixibat shows positive Phase III results in cholestatic pruritus in primary biliary cholangitis	Nov. 20	AQ
Company statement: GSK continues to show strong leadership in its Access to Medicines Index ranking	Nov. 19	PU
GSK : Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) Form 6 K	Nov. 19	PU
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) \| GSK	Nov. 19	AQ
GSK : Blenrep shows overall survival benefit in head to head DREAMM 7 phase III trial for relapsed/refractory multiple myeloma Form 6 K	Nov. 14	PU
Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma \| GSK	Nov. 14	AQ
GSK : highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need	Nov. 13	PU
GSK : BLOCK LISTING SIX MONTHLY RETURN Form 6 K	Nov. 13	PU
New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers \| GSK	Nov. 13	AQ
Gsk : Publishes Provisional 2025 Dividend Dates Form 6 K	Nov. 12	PU
ViiV HEALTHCARE DEEPENS ITS COMMITMENT TO UNDER-SERVED LGBTI COMMUNITIES, PLEDGING $7.8MILLION IN NEW FUNDING	Nov. 12	AQ
GSK : New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers	Nov. 12	PU
GSK : Q3 2024 results transcript	Nov. 01	PU
GSK : Director/Pdmr Shareholding Form 6 K	Oct. 30	PU
Glaxo: Q3 Earnings Snapshot	Oct. 30	AQ
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline \| GSK	Oct. 30	AQ
GSK : Q3 2024 results slides	Oct. 30	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : Investor disappointment as vaccines again come up short, despite the Q3 beat

October 30, 2024 at 10:26 am EDT

Emma Walmsley, CEO of GSK: Antimicrobial resistance, a public health issue

July 16, 2024 at 08:19 am EDT

GSK plc : Back on track

May 03, 2024 at 05:17 am EDT